首页> 外文期刊>Transfusion and apheresis science: official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis >The complexity of setting up clinical trials for the transfusion support of myelodysplastic syndromes: How to best serve the patients' interests?

【24h】

The complexity of setting up clinical trials for the transfusion support of myelodysplastic syndromes: How to best serve the patients' interests?

机译：为骨髓增强综合征的输血支持建立临床试验的复杂性：如何最好地为患者的利益服务？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Transfusion and apheresis science: official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis》 |2020年第2期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词
Transfusion; Clinical trial; Myelodysplasctic syndromes;

机译：输血;临床试验;骨髓增强综合征;

相似文献

外文文献
中文文献
专利

1. The complexity of setting up clinical trials for the transfusion support of myelodysplastic syndromes: How to best serve the patients' interests? [J] . Transfusion and apheresis science: official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis . 2020,第2期

机译：为骨髓增强综合征的输血支持建立临床试验的复杂性：如何最好地为患者的利益服务？
2. Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: Results from a randomized clinical trial [J] . RevickiD.A., BrandenburgN.A., MuusP., Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis . 2013,第3期

机译：来那度胺在依赖输血的低风险或中度1风险性骨髓增生异常综合征伴有染色体5q缺失的患者中与健康有关的生活质量结果：一项随机临床试验的结果
3. Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support. [J] . Pereira A, Nomdedeu M, Aguilar JL, American Journal of Hematology . 2011,第3期

机译：输血强度而非累积的红细胞输血负担决定了在长期输血支持下骨髓增生异常综合症患者的预后。
4. Azanudeoside DNA Methyltransferase Inhibitor Drugs: Update on Clinical Applications in Myelodysplastic Syndromes and Acute Myeloid Leukemia [C] . Michael Lubbert, Michael Daskalakis, Philipp N. Ser, Weissenburg Symposium Biriciana . 2016

机译：硫代稳产苷DNA甲基转移酶抑制剂药物：更新骨髓增生综合征和急性髓性白血病的临床应用
5. Chronic Bone Marrow Failure and Transfusion Patterns: Epidemiological Studies of Blood Transfusions and Outcomes in Patients with Myelodysplastic Syndromes [D] . Rydén, Jenny. 2021

机译：慢性骨髓衰竭和输血模式：骨髓增生综合征患者出血和结果的流行病学研究
6. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia [O] . Guillermo Garcia-Manero, Antonio Almeida, Aristoteles Giagounidis, 2016

机译：QUAZAR低风险MDS（AZA-MDS-003）试验的设计和原理：对IPSS低危型骨髓增生异常患者进行CC-486（口服阿扎胞苷）加最佳支持治疗与安慰剂加最佳支持治疗的随机3期研究依赖红细胞的贫血和血小板减少症引起的综合征和预后不良
7. Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support [O] . Arturo Pereira, Meritxell Nomdedeu, Josep-Lluís Aguilar, 2011

机译：输血强度，而不是累积的红细胞输血负担，决定了骨髓增强综合征患者对慢性输血支持的预后

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号